{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:39:36Z","timestamp":1791909576273,"version":"4.3.4"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline Plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019650","name":"Vir Biotechnology Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015383","name":"Foundation for Liver and Gastrointestinal Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jhep.2026.03.030","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:00:21Z","timestamp":1774857621000},"page":"61-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B \u2013 follow-up from the RETRACT-B cohort"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2746-1643","authenticated-orcid":false,"given":"Edo","family":"Dongelmans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1530-5950","authenticated-orcid":false,"given":"Grishma","family":"Hirode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"van B\u04e7mmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Juei","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7656-4695","authenticated-orcid":false,"given":"Rong-Nan","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Kilany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Hung","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":false,"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai-Kay","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian Yan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4499-0320","authenticated-orcid":false,"given":"Dag Henrik","family":"Reikvam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9598-7129","authenticated-orcid":false,"given":"Marte","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arno","family":"Furquim d'Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8581-6591","authenticated-orcid":false,"given":"Margarita","family":"Papatheodoridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3250-3177","authenticated-orcid":false,"given":"Benjamin","family":"Maasoumy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6110-7467","authenticated-orcid":false,"given":"Richard","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1970-1822","authenticated-orcid":false,"given":"Anna","family":"Pocurull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4143-1950","authenticated-orcid":false,"given":"Norah","family":"Terrault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ghany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5966-7166","authenticated-orcid":false,"given":"Asgeir","family":"Johannessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5811-6845","authenticated-orcid":false,"given":"Anna","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0572-8741","authenticated-orcid":false,"given":"Thomas","family":"Vanwolleghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4900-411X","authenticated-orcid":false,"given":"Sabela","family":"Lens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-7725","authenticated-orcid":false,"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3518-4060","authenticated-orcid":false,"given":"George","family":"Papatheodoridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0003-6241","authenticated-orcid":false,"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Chun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jhep.2026.03.030_bib1","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.030_bib2","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/HEP.0000000000001549","article-title":"AASLD\/IDSA Practice Guideline on treatment of chronic hepatitis B","volume":"83","author":"Ghany","year":"2026","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.030_bib3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/HEP.0000000000001582","article-title":"Commentary - AASLD practice guideline on treatment of chronic hepatitis B (2025 update)","volume":"83","author":"Thompson","year":"2026","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.030_bib4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12072-021-10223-5","article-title":"APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients","volume":"15","author":"Kao","year":"2021","journal-title":"Hepatol Int"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.030_bib5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.030_bib6","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jhep.2022.12.018","article-title":"A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B","volume":"78","author":"van B\u00f6mmel","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.030_bib7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.jhep.2026.03.030_bib8","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep4.1708","article-title":"Risks and benefits of discontinuation of nucleos(t)ide analogue treatment: a treatment concept for patients with HBeAg-negative chronic hepatitis B","volume":"5","author":"van B\u00f6mmel","year":"2021","journal-title":"Hepatol Commun"},{"issue":"10","key":"10.1016\/j.jhep.2026.03.030_bib9","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/infdis\/jiw412","article-title":"Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B","volume":"214","author":"H\u00f6ner Zu Siederdissen","year":"2016","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.jhep.2026.03.030_bib10","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/infdis\/jiy097","article-title":"Increased NK cell function after cessation of long-term nucleos(t)ide analogue treatment in chronic hepatitis B is associated with liver damage and HBsAg loss","volume":"217","author":"Zimmer","year":"2018","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.030_bib11","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2018.05.004","article-title":"Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B","volume":"69","author":"Rinker","year":"2018","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.030_bib12","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.jhep.2020.11.043","article-title":"Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients","volume":"74","author":"Garc\u00eda-L\u00f3pez","year":"2021","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.030_bib13","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jhep.2024.08.015","article-title":"Predictors of hepatic flares after nucleos(t)ide analogue cessation - results of a global cohort study (RETRACT-B study)","volume":"82","author":"Dongelmans","year":"2025","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.030_bib14","article-title":"Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: a systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2026.03.030_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.1037527","article-title":"Systematic review: clinical outcomes of discontinuation of oral antivirals in hepatitis B-related liver cirrhosis","volume":"10","author":"Yao","year":"2022","journal-title":"Front Public Health"},{"issue":"9","key":"10.1016\/j.jhep.2026.03.030_bib16","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.14309\/ajg.0000000000002203","article-title":"Incidence of hepatic decompensation after nucleos(t)ide analogue withdrawal: results from a large, international, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study)","volume":"118","author":"Hirode","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.030_bib17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2022.03.006","article-title":"A case of HBV-induced liver failure in the REEF-2 phase II trial: implications for finite treatment strategies in HBV 'cure'","volume":"77","author":"Agarwal","year":"2022","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.jhep.2026.03.030_bib18","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/jvh.13742","article-title":"Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B","volume":"29","author":"Liem","year":"2022","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.030_bib19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jhep.2024.03.022","article-title":"ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B","volume":"81","author":"Leung","year":"2024","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.030_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/liv.14654","article-title":"Long-term clinical outcome of HBeAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues","volume":"41","author":"Manolakopoulos","year":"2021","journal-title":"Liver Int"},{"issue":"S1","key":"10.1016\/j.jhep.2026.03.030_bib21","first-page":"S78","article-title":"DARING-B study: 5-year outcomes after nucleos (t)ide analogue (NA) cessation in Caucasian non-cirrhotic patients with HBeAgnegative chronic hepatitis B (CHBe-)","volume":"80","author":"Papatheodoridi","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.030_bib22","first-page":"77","article-title":"Final results of the Australian prospective nucleos(t)ide analogue stop study: long-term follow up identifies a higher incidence of functional cure in HBeAg-negative chronic hepatitis B","volume":"39","author":"Hume","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.03.030_bib23","article-title":"Long-term follow-up of patients in a prospective study of NA discontinuation identifies different patterns of HBsAg loss","author":"Hume","year":"2026632231","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.030_bib24","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/apt.18147","article-title":"Clinical trial: an open-label, randomised trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B","volume":"60","author":"Johannessen","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.jhep.2026.03.030_bib25","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.14309\/ajg.0000000000002176","article-title":"Withdrawal of long-term nucleotide analogue therapy in chronic hepatitis B: outcomes from the withdrawal phase of the HBRN immune active treatment trial","volume":"118","author":"Feld","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.030_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102257","article-title":"Sustained response and HBsAg loss after nucleo(s)tide analogue discontinuation in chronic hepatitis B patients: the prospective SNAP study","volume":"48","author":"Brakenhoff","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"12","key":"10.1016\/j.jhep.2026.03.030_bib27","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","article-title":"Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)","volume":"68","author":"Liem","year":"2019","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.030_bib28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/apt.15058","article-title":"Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk","volume":"49","author":"Hsu","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.jhep.2026.03.030_bib29","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/apt.14560","article-title":"Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes","volume":"47","author":"Van Hees","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.jhep.2026.03.030_bib30","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/infdis\/jix690","article-title":"Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy","volume":"217","author":"Su","year":"2018","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.jhep.2026.03.030_bib31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP3256","article-title":"DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B","volume":"23","author":"Papatheodoridis","year":"2018","journal-title":"Antivir Ther"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.030_bib32","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.030_bib33","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/gutjnl-2014-307237","article-title":"Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study","volume":"64","author":"Seto","year":"2015","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.jhep.2026.03.030_bib34","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/apt.13150","article-title":"Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B","volume":"41","author":"Chi","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"446","key":"10.1016\/j.jhep.2026.03.030_bib35","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jhep.2026.03.030_bib36","first-page":"2","article-title":"Cmprsk: subdistribution analysis of competing risks","volume":"2","author":"Gray","year":"2024","journal-title":"R Package Version"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.030_bib37","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.030_bib38","series-title":"IBM Corp. IBM SPSS statistics for windows, version 28","year":"2021"},{"key":"10.1016\/j.jhep.2026.03.030_bib39","series-title":"RStudio: integrated development environment for R","year":"2022"},{"issue":"10381","key":"10.1016\/j.jhep.2026.03.030_bib40","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.030_bib41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0033-1345716","article-title":"Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J","volume":"33","author":"Liu","year":"2013","journal-title":"Semin Liver Dis"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.030_bib42","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jhep.2022.01.007","article-title":"Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels","volume":"76","author":"Sonneveld","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.030_bib43","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.030_bib44","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1053\/j.gastro.2015.12.047","article-title":"Posttreatment hepatitis B surface antigen seroreversion: the bane of combination therapy in chronic hepatitis B?","volume":"150","author":"Sonneveld","year":"2016","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1016\/j.jhep.2026.03.030_bib45","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1056\/NEJMoa2405485","article-title":"Xalnesiran with or without an immunomodulator in chronic hepatitis B","volume":"391","author":"Hou","year":"2024","journal-title":"New Engl J Med"},{"issue":"9","key":"10.1016\/j.jhep.2026.03.030_bib46","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2468-1253(23)00148-6","volume":"8","author":"Yuen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.030_bib47","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jhep.2024.08.010","article-title":"Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B","volume":"82","author":"Buti","year":"2025","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.030_bib48","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jhep.2024.03.046","article-title":"JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2","volume":"81","author":"Agarwal","year":"2024","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.030_bib49","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.030_bib50","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.cgh.2024.07.031","article-title":"Baseline viral load and on-treatment hepatocellular carcinoma risk in chronic hepatitis B: a multinational cohort study","volume":"23","author":"Choi","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.030_bib51","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.030_bib52","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/liv.15128","article-title":"Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: a multicentre cohort study","volume":"42","author":"Papatheodoridi","year":"2022","journal-title":"Liver Int"},{"issue":"10","key":"10.1016\/j.jhep.2026.03.030_bib53","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/apt.13409","article-title":"Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis","volume":"42","author":"Chen","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.jhep.2026.03.030_bib54","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/jvh.12683","article-title":"Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy","volume":"24","author":"Hung","year":"2017","journal-title":"J Viral Hepat"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.030_bib55","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/HEP.0000000000000575","article-title":"Hepatocellular carcinoma reduced, HBsAg loss increased and survival improved after finite therapy in hepatitis B patients with cirrhosis","volume":"79","author":"Jeng","year":"2024","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.030_bib56","doi-asserted-by":"crossref","first-page":"E95","DOI":"10.1097\/HEP.0000000000000639","article-title":"Letter to the Editor: benefits of stopping therapy in patients with cirrhotic hepatitis B, true effect or residual confounding?","volume":"79","author":"Dongelmans","year":"2024","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.030_bib57","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3350\/cmh.2016.0045","article-title":"The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy","volume":"22","author":"Varbobitis","year":"2016","journal-title":"Clin Mol Hepatol"},{"issue":"12","key":"10.1016\/j.jhep.2026.03.030_bib58","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1016\/j.cgh.2023.03.024","article-title":"Association between the presence of metabolic comorbidities and liver-related events in patients with chronic hepatitis B","volume":"21","author":"Patmore","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.030_bib59","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.030_bib60","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jhep.2023.06.002","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference","volume":"79","author":"Ghany","year":"2023","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826001856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826001856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T16:31:11Z","timestamp":1783787471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826001856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0168827826001856"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.03.030","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B \u2013 follow-up from the RETRACT-B cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.03.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}